--- title: "Climb Bio (CLYM) news: offering and lawsuit" url: "https://aibio.space/companies/climb-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CLYM offering and lawsuit news: Climb Bio sets up $22,350,000 at-the-market stock program with Oppenheimer. Climb Bio, Inc. (NASDAQ: CLYM), United States." --- CLYM Climb Bio, Inc. NASDAQ · United States # Climb Bio (CLYM) news CLYM offering and lawsuit news Legal · 2025-12-31 ## [Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment](https://aibio.space/news/climb-bio-sues-alumis-acelyrin-3-million-budoprutug-milestone-payment/) Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment. ## Latest Climb Bio news 1. 2025-12-11 Financings [Climb Bio agrees to swap 20,440,000 RA Capital shares for a pre-funded warrant](https://aibio.space/news/climb-bio-agrees-swap-20-440-000-ra-capital-shares-pre-funded-warrant/) Climb Bio agreed on December 11, 2025 to take back 20,440,000 shares from an entity affiliated with RA Capital in exchange for a pre-funded warrant. After the exchange, RA Capital and its affiliates will hold about 23.0% of the voting power, and the filing describes no cash payment to the company. 2. 2025-03-25 Financings [Climb Bio sets up $22,350,000 at-the-market stock program with Oppenheimer](https://aibio.space/news/climb-bio-sets-up-22-350-000-market-stock-program-oppenheimer/) The sales agent earns up to 3.0% of gross sales. Climb Bio reported $212.5 million of cash and securities at year end and expects to fund operations through 2027. ## Climb Bio at a glance - **Ticker**: CLYM - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $183.1 million ### Related companies - [Novavax](https://aibio.space/companies/novavax/) NASDAQ: NVAX - [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) NYSE: RCUS - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) NASDAQ: ALMR - [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) NASDAQ: DTIL - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Passage Bio](https://aibio.space/companies/passage-bio/) NASDAQ: PASG ### Also on NASDAQ - [Tectonic Therapeutic](https://aibio.space/companies/tectonic-therapeutic/) TECX - [BIOHARVEST SCIENCES INC.](https://aibio.space/companies/bioharvest-sciences/) BHST - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) ALMR - [Obsidian Therapeutics](https://aibio.space/companies/obsidian-therapeutics/) OBX - [KESTRA MEDICAL TECHNOLOGIES, LTD.](https://aibio.space/companies/kestra-medical-technologies/) KMTS - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) ALDX ## Climb Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$46.7 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | [$14.3 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | | Net income (loss) | [-$59.9 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | [-$73.9 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | | Cash from operations | [-$54.4 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | [-$15.6 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | | Cash and equivalents | [$35.7 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526336774/) | [$87.2 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | | Short-term investments | [$65.4 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526336774/) | [$63.7 million](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092546/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $44.1 million, plus short-term investments of $139.0 million, $183.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Climb Bio Has Climb Bio raised money recently? Our latest story on this, dated Mar 25, 2025: "Climb Bio sets up $22,350,000 at-the-market stock program with Oppenheimer". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/climb-bio-sets-up-22-350-000-market-stock-program-oppenheimer/). Is Climb Bio involved in a lawsuit? Our latest story on this, dated Dec 31, 2025: "Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/climb-bio-sues-alumis-acelyrin-3-million-budoprutug-milestone-payment/). What is the ticker symbol of Climb Bio? Climb Bio, Inc. trades under the ticker CLYM on NASDAQ. Where is Climb Bio listed? Climb Bio, Inc. is listed on NASDAQ. What is the SEC CIK of Climb Bio? The SEC Central Index Key (CIK) for Climb Bio, Inc. is 1768446. Its filings are on SEC EDGAR. How many shares does Climb Bio have outstanding? 57,436,255 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Climb Bio listed under? Our directory records Climb Bio, Inc. under United States. What does Climb Bio do? Our directory classifies Climb Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Climb Bio? The ISIN recorded for Climb Bio, Inc. is US28658R1068. Does aibio.space cover Climb Bio? aibio.space lists Climb Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Climb Bio incorporated? SEC records list its state or country of incorporation as DE. Is Climb Bio profitable? Climb Bio, Inc. reported a net loss of $59.9 million for the fiscal year ended Dec 31, 2025, and used $54.4 million of cash in operations, per its annual report to the SEC. How much does Climb Bio spend on research and development? $46.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Climb Bio have? $183.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Climb Bio (CLYM) stock news? Our latest story on Climb Bio, dated Dec 31, 2025: "Climb Bio sues Alumis and Acelyrin over $3 million budoprutug milestone payment". Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment. [Source](https://aibio.space/news/climb-bio-sues-alumis-acelyrin-3-million-budoprutug-milestone-payment/). ## Investor discussion: Climb Bio Members talk about Climb Bio (CLYM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Climb Bio, newest first. Each line links the filing it comes from. 1. 2026-06-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1768446/000119312526269510/d93164d424b5.htm) 2. 2026-05-29 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1768446/000119312526248243/d83073ds3.htm) 3. 2026-04-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1768446/000119312526183711/d153155dex991.htm) 4. 2025-12-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1768446/000119312525315108/d48098d8k.htm) 5. 2025-03-25 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1768446/000119312525062602/d894946d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CLYM on TradingView](https://www.tradingview.com/symbols/NASDAQ-CLYM/). ## SEC filings and registration - **SEC name**: Climb Bio, Inc. - **CIK**: 1768446 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CLYM (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 20 WILLIAM STREET, WELLESLEY HILLS, MA - **Phone**: 1-866-857-2596 - **Shares outstanding**: 57,436,255 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: Eliem Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033d8k.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1768446/000119312526350596/d328636d8k.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1768446/000119312526336774/clym-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/clym-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1768446/000119312526292567/d61061d8k.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1768446/000119312526269567/d92589d8k.htm) filed 2026-06-12 - [424B5](https://www.sec.gov/Archives/edgar/data/1768446/000119312526269510/d93164d424b5.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/d63753d8k.htm) filed 2026-06-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001768446), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Climb Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CLYM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Climb Bio, Inc. - **Ticker**: CLYM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US28658R1068 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CLYM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/climb-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Climb Bio (CLYM) news: offering and lawsuit", 2026-10-31, https://aibio.space/companies/climb-bio/